The Role of Ketogenic Metabolic Therapy on the Brain in Serious Mental Illness: A Review-Journal of Psychiatry and Brain Science-CSCIED科技核心评价数据库

推荐文章

Soil Health as a Dynamic, Plant-Specific Attribute: Redefining Its Role Beyond Traditional Soil Quality Indicators

The Role of Ketogenic Metabolic Therapy on the Brain in Serious Mental Illness: A Review

The Role of Ketogenic Metabolic Therapy on the Brain in Serious Mental Illness: A Review

ES评分9.5 浏览量：1257 下载量：7

全文阅读下载引用收藏评论

DOI	10.20900/jpbs.20220009
刊名	Journal of Psychiatry and Brain Science JPBS
年，卷(期)	2022, 7(5)
作者	Shebani Sethi,Judith M. Ford*,
作者单位	1 Metabolic Psychiatry, Stanford University School of Medicine, Stanford, CA 94305, USA; 2 Mental Health, San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121, USA; 3 Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA 94121, USA
Abstract	In search of interventions targeting brain dysfunction and underlying cognitive impairment in schizophrenia, we look at the brain and beyond to the potential role of dysfunctional systemic metabolism on neural network instability and insulin resistance in serious mental illness. We note that disrupted insulin and cerebral glucose metabolism are seen even in medication-naïve first-episode schizophrenia, suggesting that people with schizophrenia are at risk for Type 2 diabetes and cardiovascular disease, resulting in a shortened life span. Although glucose is the brain’s default fuel, ketones are a more efficient fuel for the brain. We highlight evidence that a ketogenic diet can improve both the metabolic and neural stability profiles. Specifically, a ketogenic diet improves mitochondrial metabolism, neurotransmitter function, oxidative stress/inflammation, while also increasing neural network stability and cognitive function. To reverse the neurodegenerative process, increasing the brain’s access to ketone bodies may be needed. We describe evidence that metabolic, neuroprotective, and neurochemical benefits of a ketogenic diet potentially provide symptomatic relief to people with schizophrenia while also improving their cardiovascular or metabolic health. We review evidence for KD side effects and note that although high in fat it improves various cardiovascular and metabolic risk markers in overweight/obese individuals. We conclude by calling for controlled clinical trials to confirm or refute the findings from anecdotal and case reports to address the potential beneficial effects of the ketogenic diet in people with serious mental illness.
KeyWord	schizophrenia; bipolar disorder; insulin resistance; metabolism; functional connectivity; neural network stability; psychotic symptoms; metabolic psychiatry
基金项目
页码	-

参考文献
相关文献

1.
Mujica-Parodi LR, Amgalan A, Sultan SF, Antal B, Sun X, Skiena S, et al. Diet modulates brain network stability, a biomarker for brain aging, in young adults. Proc Natl Acad Sci U S A. 2020;117:6170-7.

2.
Kossoff EH, Krauss GL, McGrogan JR, Freeman JM. Efficacy of the Atkins diet as therapy for intractable epilepsy. Neurology. 2003;61:1789-91.

3.
Marosi K, Kim SW, Moehl K, Scheibye-Knudsen M, Cheng A, Cutler R, et al. 3-Hydroxybutyrate regulates energy metabolism and induces BDNF expression in cerebral cortical neurons. J Neurochem. 2016;139:769-81.

4.
Lopresti AL, Jacka FN. Diet and bipolar disorder: A review of its relationship and potential therapeutic mechanisms of action. J Altern Complement Med. 2015;21:733-9.

5.
Norwitz NG, Dalai SS, Palmer CM. Ketogenic diet as a metabolic treatment for mental illness. Curr Opin Endocrinol Diabetes Obes. 2020;27:269-74.

6.
Morris G, Puri BK, Carvalho A, Maes M, Berk M, Ruusunen A, et al. Induced Ketosis as a Treatment for Neuroprogressive Disorders: Food for Thought? Int J Neuropsychopharmacol. 2020;23:366-84.

7.
Antal B, McMahon LP, Sultan SF, Lithen A, Wexler DJ, Dickerson B, et al. Type 2 diabetes mellitus accelerates brain aging and cognitive decline: Complementary findings from UK Biobank and meta-analyses. Elife. 2022 May 24;11:e73138.

8.
Watson KT, Simard JF, Henderson VW, Nutkiewicz L, Lamers F, Rasgon N, et al. Association of Insulin Resistance with Depression Severity and Remission Status: Defining a Metabolic Endophenotype of Depression. JAMA Psychiatry. 2021;78:439-41.

9.
Schnaider Beeri M, Goldbourt U, Silverman JM, Noy S, Schmeidler J, Ravona-Springer R, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004;63:1902-7.

10.
Van Eersel MEA, Joosten H, Gansevoort RT, Dullaart RPF, Slaets JPJ, Izaks GJ. The interaction of age and type 2 diabetes on executive function and memory in persons aged 35 years or older. PLoS One. 2013;8:e82991.

11.
Brosch K, Stein F, Schmitt S, Pfarr J-K, Ringwald KG, Thomas-Odenthal F, et al. Reduced hippocampal gray matter volume is a common feature of patients with major depression, bipolar disorder, and schizophrenia spectrum disorders. Mol Psychiatry. 2022 Jul 15. doi: 10.1038/s41380-022-01687-4

12.
Brietzke E, Mansur RB, Subramaniapillai M, Balanzá-Martínez V, Vinberg M, González-Pinto A, et al. Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. Neurosci Biobehav Rev. 2018;94:11-6.

13.
Kraeuter AK, Phillips R, Sarnyai Z. Ketogenic therapy in neurodegenerative and psychiatric disorders: From mice to men. Prog Neuro-Psychopharmacol Biol Psychiatry. 2020;101:109913.

14.
McDonald TJW, Cervenka MC. Ketogenic Diets for Adult Neurological Disorders. Neurotherapeutics. 2018;15:1018-31.

15.
Yu B, Ozveren R, Dalai SS. Ketogenic diet as a metabolic therapy for bipolar disorder: Clinical developments. Neurosci Biobehav Rev. 2018 Nov;94:11-6.

16.
Miller VJ, Villamena FA, Volek JS. Nutritional ketosis and mitohormesis: Potential implications for mitochondrial function and human health. J Nutr Metab. 2018 Feb 11;2018:5157645.

17.
Kapogiannis D, Avgerinos KI. Brain glucose and ketone utilization in brain aging and neurodegenerative diseases. Int Rev Neurobiol. 2020;154:79-110.

18.
Han YM, Ramprasath T, Zou MH. β-hydroxybutyrate and its metabolic effects on age-associated pathology. Exp Mol Med. 2020;52:548-55.

19.
Tao Y, Leng SX, Zhang H. Ketogenic diet: an effective treatment approach for neurodegenerative diseases. Curr Neuropharmacol. 2022 Aug 30. doi: 10.2174/1570159X20666220830102628

20.
Raichle ME, Gusnard DA. Appraising the brain’s energy budget. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10237-9.

21.
Veech RL. The therapeutic implications of ketone bodies: The effects of ketone bodies in pathological conditions: Ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fat Acids. 2004;70:309-19.

22.
Wijtenburg SA, Kapogiannis D, Korenic SA, Mullins RJ, Tran J, Gaston F, et al. Brain insulin resistance and altered brain glucose are related to memory impairments in schizophrenia. Schizophr Res. 2019;208:324-30.

23.
McClernon FJ, Yancy WS, Eberstein JA, Atkins RC, Westman EC. The effects of a low-carbohydrate ketogenic diet and a low-fat diet on mood, hunger, and other self-reported symptoms. Obesity. 2007;15:182.

24.
Mohorko N, Černelič-Bizjak M, Poklar-Vatovec T, Grom G, Kenig S, Petelin A, et al. Weight loss, improved physical performance, cognitive function, eating behavior, and metabolic profile in a 12-week ketogenic diet in obese adults. Nutr Res. 2019;62:64-77.

25.
El-Mallakh RS, Paskitti ME. The ketogenic diet may have mood-stabilizing properties. Med Hypotheses. 2001;57:724-6.

26.
Cunnane SC, Courchesne-Loyer A, St-Pierre V, Vandenberghe C, Pierotti T, Fortier M, et al. Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer’s disease. Ann N Y Acad Sci. 2016;1367:12-20.

27.
Sato K, Kashiwaya Y, Keon CA, Tsuchiya N, King MT, Radda GK, et al. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J. 1995;9:651-8.

28.
Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia. 2007;48:43-58.

29.
Rusek M, Pluta R, Ułamek-Kozioł M, Czuczwar SJ. Ketogenic diet in alzheimer’s disease. Int J Mol Sci. 2019;20:3892.

30.
Morris G, Puri BK, Maes M, Olive L, Berk M, Carvalho AF. The role of microglia in neuroprogressive disorders: mechanisms and possible neurotherapeutic effects of induced ketosis. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Apr 20;99:109858.

31.
Olson CA, Vuong HE, Yano JM, Liang QY, Nusbaum DJ, Hsiao EY. The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet. Cell. 2018;173:1728-41.e13.

32.
Kraeuter AK, Mashavave T, Suvarna A, van den Buuse M, Sarnyai Z. Effects of beta-hydroxybutyrate administration on MK-801-induced schizophrenia-like behaviour in mice. Psychopharmacology. 2020;237:1397-405.

33.
Norwitz NG, Hu MT, Clarke K. The mechanisms by which the ketone body d-β-hydroxybutyrate may improve the multiple cellular pathologies of parkinson’s disease. Front Nutr. 2019 May 14;6:63.

34.
Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: A systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun. 2019;81:24-40.

35.
Marques TR, Ashok AH, Pillinger T, Veronese M, Turkheimer FE, Dazzan P,et al. Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies. Psychol Med. 2019;49:2186-96.

36.
Athinarayanan SJ, Adams RN, Hallberg SJ, McKenzie AL, Bhanpuri NH, Campbell WW, et al. Long-term effects of a novel continuous remote care intervention including nutritional ketosis for the management of type 2 diabetes: A 2-year nonrandomized clinical trial. Front Endocrinol. 2019;10:348.

37.
Hallberg SJ, McKenzie AL, Williams PT, Bhanpuri NH, Peters AL, Campbell WW, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018;9:583-612.

38.
McKenzie AL, Hallberg SJ, Creighton BC, Volk BM, Link TM, Abner MK, et al. A novel intervention including individualized nutritional recommendations reduces hemoglobin A1c level, medication use, and weight in type 2 diabetes. JMIR Diabetes. 2017;2:e6981.

39.
Virta Health. Virta Health Highlights Lasting, Transformative Health Improvements In 5-Year Diabetes Reversal Study, Available from: https://www.virtahealth.com/blog/virta-sustainable-health-improvements-5-year-diabetes-reversal-study. Accessed 2022 Aug 29.

40.
Athinarayanan SJ, Hallberg SJ, McKenzie AL, Lechner K, King S, McCarter JP, et al. Impact of a 2-year trial of nutritional ketosis on indices of cardiovascular disease risk in patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19:1-13.

41.
Parry-Strong A, Wright-McNaughten M, Weatherall M, Hall RM, Coppell KJ, Barthow C, et al. Very low carbohydrate (ketogenic) diets in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2022 Aug 15. doi: 10.1111/dom.14837

42.
Martin-McGill KJ, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev. 2020 Jun 24;6(6):CD001903.

43.
Liu H, Yang Y, Wang Y, Tang H, Zhang F, Zhang Y, et al. Ketogenic diet for treatment of intractable epilepsy in adults: A meta-analysis of observational studies. Epilepsia Open. 2018;3:9-17.

44.
Kverneland M, Molteberg E, Iversen PO, Veierød MB, Taubøll E, Selmer KK, et al. Effect of modified Atkins diet in adults with drug-resistant focal epilepsy: A randomized clinical trial. Epilepsia. 2018;59:1567-76.

45.
Wilkins HM, Swerdlow RH. Amyloid precursor protein processing and bioenergetics. Brain Res Bull. 2017;133:71-9.

46.
Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL. d-β-hydroxybutyrate protects neurons in models of Alzheimer’s and Parkinson’s disease. Proc Natl Acad Sci U S A. 2000;97:5440-4.

47.
Van Der Auwera I, Wera S, Van Leuven F, Henderson ST. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer’s disease. Nutr Metab. 2005;2:1-8.

48.
Phelps JR, Siemers SV, El-Mallakh RS. The ketogenic diet for type II bipolar disorder. Neurocase. 2013;19:423-6.

49.
Campbell I, Campbell H. A pyruvate dehydrogenase complex disorder hypothesis for bipolar disorder. Med Hypotheses. 2019 Sep;130:109263.

50.
Campbell I, Campbell H. Mechanisms of insulin resistance, mitochondrial dysfunction and the action of the ketogenic diet in bipolar disorder. Focus on the PI3K/AKT/HIF1-a pathway. Med Hypotheses. 2020;145:110299.

51.
Shamshtein D, Liwinski T. Ketogenic Therapy for Major Depressive Disorder: A Review of Neurobiological Evidence. Recent Prog Nutr. 2021;2:1.

52.
Ricci A, Idzikowski MA, Soares CN, Brietzke E. Exploring the mechanisms of action of the antidepressant effect of the ketogenic diet. Rev Neurosci. 2020;31:637-48.

53.
Phillips MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, Lynch CDP. Low-fat versus ketogenic diet in Parkinson’s disease: A pilot randomized controlled trial. Mov Disord. 2018;33:1306-14.

54.
Henkel ND, Wu X, O’Donovan SM, Devine EA, Jiron JM, Rowland LM, et al. Schizophrenia: a disorder of broken brain bioenergetics. Mol Psychiatry. 2022;27:2393-404.

55.
Tourigny DS, Karim MKA, Echeveste R, Kotter MRN, OʼNeill JS. Energetic substrate availability regulates synchronous activity in an excitatory neural network. PLoS One. 2019;14:e0220937.

56.
Masino SA, Rho JM. Metabolism and epilepsy: Ketogenic diets as a homeostatic link. Brain Res. 2019;1703:26-30.

57.
Zarnowska IM. Therapeutic use of the ketogenic diet in refractory epilepsy: What we know and what still needs to be learned. Nutrients. 2020;12:1-23.

58.
Masino S. Ketogenic Diet and Metabolic Therapies: Expanded Roles in Health and Disease. 2nd ed. Oxford (UK): Oxford University Press; 2022.

59.
Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-30.

60.
Najas-García A, Rufián S, Rojo E. Neurodevelopment or neurodegeneration: Review of theories of schizophrenia Related papers Neurodegenerat ive Aspect s in Vulnerabilit y t o Schizophrenia Spect rum Disorders. Actas Esp Psiquiatr. 2014;42:185-95.

61.
Bozzi Y, Casarosa S, Caleo M. Epilepsy as a neurodevelopmental disorder. Front Psychiatry. 2012;3:19.

62.
Pillinger T, Beck K, Gobjila C, Donocik JG, Jauhar S, Howes OD, et al. Impaired glucose homeostasis in first-episode schizophrenia: A systematic review and meta-analysis. JAMA Psychiatry. 2017;74:261-9.

63.
Reilly JL, Harris MSH, Keshavan MS, Sweeney JA. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry. 2006;63:1189-97.

64.
Kraeuter AK, Loxton H, Lima BC, Rudd D, Sarnyai Z. Ketogenic diet reverses behavioral abnormalities in an acute NMDA receptor hypofunction model of schizophrenia. Schizophrenia Res. 2015;169:491-3.

65.
Nguyen TT, Eyler LT, Jeste DV. Systemic biomarkers of accelerated aging in schizophrenia: A critical review and future directions. Schizophr Bull. 2018;44:398-408.

66.
Ancoli-Israel S, Martin J, Jones DW, Caligiuri M, Patterson T, Harris MJ, et al. Sleep-disordered breathing and periodic limb movements in sleep in older patients with schizophrenia. Biol Psychiatry. 1999;45:1426-32.

67.
Kirkpatrick B, Messias E, Harvey PD, Fernandez-Egea E, Bowie CR. Is schizophrenia a syndrome of accelerated aging? Schizophr Bull. 2008;34:1024-32.

68.
Rajasekaran A, Venkatasubramanian G, Berk M, Debnath M. Mitochondrial dysfunction in schizophrenia: Pathways, mechanisms and implications. Neurosci Biobehav Rev. 2015;48:10-21.

69.
Hackinger S, Prins B, Mamakou V, Zengini E, Marouli E, Brčić L, et al. Evidence for genetic contribution to the increased risk of type 2 diabetes in schizophrenia. Transl Psychiatry. 2018;8:1-10.

70.
Liu Y, Li Z, Zhang M, Deng Y, Yi Z, Shi T. Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. BMC Med Genomics. 2013;6:1-14.

71.
Raichle ME, MacLeod AM, Snyder AZ, Shulman GL. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98:676-82.

72.
Hebb DO. The Organization of Behavior: A Neuropsychological Theory. New York (NY, US): John Wiley & Sons, Ltd; 1949.

73.
Sheffield JM, Barch DM. Cognition and resting-state functional connectivity in schizophrenia. Neurosci Biobehav Rev. 2016;61:108-20.

74.
Zhang D, Snyder AZ, Shimony JS, Fox MD, Raichle ME. Noninvasive functional and structural connectivity mapping of the human thalamocortical system. Cereb Cortex. 2010;20:1187-94.

75.
Espinoza FA, Vergara VM, Damaraju E, Henke KG, Faghiri A, Turner JA, et al. Characterizing whole brain temporal variation of functional connectivity via zero and first order derivatives of sliding window correlations. Front Neurosci. 2019;13:634.

76.
Damaraju E, Allen EA, Belger A, Ford JM, McEwen S, Mathalon DH, et al. Dynamic functional connectivity analysis reveals transient states of dysconnectivity in schizophrenia. NeuroImage Clin. 2014;5:298-308.

77.
Faghiri A, Iraji A, Damaraju E, Belger A, Ford J, Mathalon D, et al. Weighted average of shared trajectory: A new estimator for dynamic functional connectivity efficiently estimates both rapid and slow changes over time. J Neurosci Methods. 2020;334:108600.

78.
Iraji A, Deramus TP, Lewis N, Yaesoubi M, Stephen JM, Erhardt E, et al. The spatial chronnectome reveals a dynamic interplay between functional segregation and integration. Hum Brain Mapp. 2019;40:3058-77.

79.
Brownlow ML, Jung SH, Moore RJ, Bechmann N, Jankord R. Nutritional ketosis affects metabolism and behavior in sprague-dawley rats in both control and chronic stress environments. Front Mol Neurosci. 2017;10:129.

80.
Sullivan CR, Mielnik CA, Funk A, OʼDonovan SM, Bentea E, Pletnikov M, et al. Measurement of lactate levels in postmortem brain, iPSCs, and animal models of schizophrenia. Sci Rep. 2019;9:1-7.

81.
Kraeuter AK, van den Buuse M, Sarnyai Z. Ketogenic diet prevents impaired prepulse inhibition of startle in an acute NMDA receptor hypofunction model of schizophrenia. Schizophr Res. 2019;206:244-50.

82.
Bostock ECS, Kirkby KC, Taylor BVM. The current status of the ketogenic diet in psychiatry. Front Psychiatry. 2017;8:43.

83.
Kraft BD, Westman EC. Schizophrenia, gluten, and low-carbohydrate, ketogenic diets: A case report and review of the literature. Nutr Metab. 2009;6:1-3.

84.
Pacheco A, Easterling WS, Pryer MW. A pilot study of the ketogenic diet in schizophrenia. Am J Psychiatry. 1965;121:1110-1.

85.
Palmer CM. Ketogenic diet in the treatment of schizoaffective disorder: Two case studies. Schizophr Res. 2017;189:208-9.

86.
Gilbert-Jaramillo J, Vargas-Pico D, Espinosa-Mendoza T, Falk S, Llanos-Fernandez K, Guerrero-Haro J, et al. The effects of the ketogenic diet on psychiatric symptomatology, weight and metabolic dysfunction in schizophrenia patients. Clin Nutr Metab. 2018;1:1-5.

87.
Danan A, Westman EC, Saslow LR, Ede G. The Ketogenic Diet for Refractory Mental Illness: A Retrospective Analysis of 31 Inpatients. Front Psychiatry. 2022;13:1421.

88.
Hermes EDA, Sokoloff D, Stroup TS, Rosenheck RA. Minimum clinically important difference in the positive and negative syndrome scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J Clin Psychiatry. 2012;73:526-32.

89.
Oz R, Wakeham D, Ketter T, Ketter T, Hooshmand F, Ketter T, et al. Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients with Bipolar or Schizophrenia Illness, Pilot Trial Preliminary Analysis. In Proceedings of 5th Annual Metabolic Health Summit; 2022 May 5-8; Santa Barba, CA, USA. Santa Barba (CA, USA): Metabolic Health Summit; 2022.

90.
Moreno B, Bellido D, Sajoux I, Goday A, Saavedra D, Crujeiras AB, et al. Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity. Endocrine. 2014;47:793-805.

91.
Genco A, Ienca R, Ernesti I, Maselli R, Casella G, Bresciani S, et al. Improving Weight Loss by Combination of Two Temporary Antiobesity Treatments. Obes Surg. 2018;28:3733-7.

92.
Goday A, Bellido D, Sajoux I, Crujeiras AB, Burguera B, García-Luna PP, et al. Short-Term safety, tolerability and efficacy of a very low-calorie-ketogenic diet interventional weight loss program versus hypocaloric diet in patients with type 2 diabetes mellitus. Nutr Diabetes. 2016;6:e230.

93.
Johnstone AM, Horgan GW, Murison SD, Bremner DM, Lobley GE. Effects of a high-protein ketogenic diet on hunger, appetite, and weight loss in obese men feeding ad libitum. Am J Clin Nutr. 2008;87:44-55.

94.
Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, et al. A Low-Carbohydrate as Compared with a Low-Fat Diet in Severe Obesity. N Engl J Med. 2003;348:2074-81.

95.
Yancy WS, Olsen MK, Guyton JR, Bakst RP, Westman EC. A Low-Carbohydrate, Ketogenic Diet versus a Low-Fat Diet to Treat Obesity and Hyperlipidemia: A Randomized, Controlled Trial. Ann Intern Med. 2004 May 18;140(10):769-77.

96.
Yancy WS, Westman EC, McDuffie JR, Grambow SC, Jeffreys AS, Bolton J, et al. A randomized trial of a low-carbohydrate diet vs orlistat plus a low-fat diet for weight loss. Arch Intern Med. 2010;170:136-45.

97.
Bhanpuri NH, Hallberg SJ, Williams PT, McKenzie AL, Ballard KD, Campbell W, et al. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: An open label, non-randomized, controlled study. Cardiovasc Diabetol. 2018;17:1-16.

98.
Hyde PN, Sapper TN, Crabtree CD, LaFountain RA, Bowling ML, Buga A, et al. Dietary carbohydrate restriction improves metabolic syndrome independent of weight loss. JCI Insight. 2019 Jun 20;4(12):e128308.

99.
Hall KD, Chen KY, Guo J, Lam YY, Leibel RL, Mayer LE, et al. Energy expenditure and body composition changes after an isocaloric ketogenic diet in overweight and obese men. Am J Clin Nutr. 2016;104:324-33.

100.
Saslow LR, Mason AE, Kim S, Goldman V, Ploutz-Snyder R, Bayandorian H, et al. An online intervention comparing a very low-carbohydrate ketogenic diet and lifestyle recommendations versus a plate method diet in overweight individuals with type 2 diabetes: A randomized controlled trial. J Med Internet Res. 2017 Feb 13;19(2):e36.

101.
Klein P, Janousek J, Barber A, Weissberger R. Ketogenic diet treatment in adults with refractory epilepsy. Epilepsy Behav. 2010;19:575-9.

102.
Cervenka MC, Patton K, Eloyan A, Henry B, Kossoff EH. The impact of the modified Atkins diet on lipid profiles in adults with epilepsy. Nutr Neurosci. 2016;19:131-7.

103.
Ye F, Li XJ, Jiang WL, Sun H-B, Liu J. Efficacy of and patient compliance with a ketogenic diet in adults with intractable epilepsy: A meta-analysis. J Clin Neurol. 2015;11:26-31.

104.
Cervenka MC, Henry BJ, Felton EA, Patton K, Kossoff EH. Establishing an Adult Epilepsy Diet Center: Experience, efficacy and challenges. Epilepsy Behav. 2016;58:61-8.

105.
Leffler DA, Edwards-George J, Dennis M, Schuppan D, Cook F, Franko DL, et al. Factors that influence adherence to a gluten-free diet in adults with celiac disease. Dig Dis Sci. 2008;53:1573-81.

106.
Féart C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues J-F, et al. Adherence to a mediterranean diet, cognitive decline, and risk of dementia. JAMA. 2009;302:638-48.

引用本文

Shebani Sethi,Judith M. Ford*. The Role of Ketogenic Metabolic Therapy on the Brain in Serious Mental Illness: A Review, Journal of Psychiatry and Brain Science. 2022; 7; (5). https://doi.org/10.20900/jpbs.20220009.

文献评论

2025-09-22 09:35:57陶**南京农业******已认证✔

这篇论文针对精神分裂症患者脑功能障碍和潜在认知障碍，重点关注了大脑及其以外的系统代谢功能障碍对严重精神疾病患者神经网络不稳定和胰岛素抵抗的潜在作用，证明生酮饮食的代谢、神经保护和神经化学益处可能为精神分裂症患者提供症状缓解，同时也改善他们的心血管或代谢健康。

2025-09-17 04:17:19h**

文章对精神分裂症患者脑功能障碍和潜在认知障碍的干预措施方面进行了比较深入的综述，对精神分裂症、双相情感障碍等严重的精神疾病的治疗具有重要的借鉴意义。

相关学者

相关机构

推荐文章